A citation-based method for searching scientific literature

Matthew K Smith, Jay Pai, Remo Panaccione, Paul Beck, Jose G Ferraz, Humberto Jijon. BMC Gastroenterol 2019
Times Cited: 23







List of co-cited articles
186 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Wolfgang Hueber, Bruce E Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch, Peter D R Higgins, Jan Wehkamp, Brian G Feagan, Michael D Yao, Marek Karczewski,[...]. Gut 2012
975
73

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.
Stephan R Targan, Brian Feagan, Severine Vermeire, Remo Panaccione, Gil Y Melmed, Carol Landers, Dalin Li, Chris Russell, Richard Newmark, Nan Zhang,[...]. Am J Gastroenterol 2016
210
52

Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
43

The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis.
Andrew Blauvelt, Andrea Chiricozzi. Clin Rev Allergy Immunol 2018
235
39

Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion.
Jingzhou Wang, Arvin Bhatia, Noa Krugliak Cleveland, Nina Gupta, Sushila Dalal, David T Rubin, Atsushi Sakuraba. ACG Case Rep J 2018
40
39

Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents.
Akihiro Yamada, Jingzhou Wang, Yuga Komaki, Fukiko Komaki, Dejan Micic, Atsushi Sakuraba. Aliment Pharmacol Ther 2019
28
39

Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease.
Megan Hohenberger, Leah A Cardwell, Elias Oussedik, Steven R Feldman. J Dermatolog Treat 2018
93
34

Severe de novo Ulcerative Colitis following Ixekizumab Therapy.
Jobin Philipose, Moiz Ahmed, Pretty S Idiculla, Stephen M Mulrooney, Vivek V Gumaste. Case Rep Gastroenterol 2018
16
50

Inflammatory Bowel Disease Onset During Secukinumab Treatment: Real Concern or Just an Expression of Dysregulated Immune Response?
Walter Fries, Alessandra Belvedere, Maria Cappello, Ambrogio Orlando, Gianluca Trifirò. Clin Drug Investig 2019
16
50

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
Stefan Schreiber, Jean-Frederic Colombel, Brian G Feagan, Kristian Reich, Atul A Deodhar, Iain B McInnes, Brian Porter, Ayan Das Gupta, Luminita Pricop, Todd Fox. Ann Rheum Dis 2019
97
34

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Kenneth B Gordon, Andrew Blauvelt, Kim A Papp, Richard G Langley, Thomas Luger, Mamitaro Ohtsuki, Kristian Reich, David Amato, Susan G Ball, Daniel K Braun,[...]. N Engl J Med 2016
473
26

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.
Kristian Reich, Craig Leonardi, Richard G Langley, Richard B Warren, Hervé Bachelez, Ricardo Romiti, Mamitaro Ohtsuki, Wen Xu, Nayan Acharya, Kathleen Solotkin,[...]. J Am Acad Dermatol 2017
60
26

Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability.
Jacob S Lee, Cristina M Tato, Barbara Joyce-Shaikh, Muhammet F Gulen, Corinne Cayatte, Yi Chen, Wendy M Blumenschein, Michael Judo, Gulesi Ayanoglu, Terrill K McClanahan,[...]. Immunity 2015
411
26

Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice.
Atsuhiro Ogawa, Akira Andoh, Yoshio Araki, Tadao Bamba, Yoshihide Fujiyama. Clin Immunol 2004
360
26

Increased expression of interleukin 17 in inflammatory bowel disease.
S Fujino, A Andoh, S Bamba, A Ogawa, K Hata, Y Araki, T Bamba, Y Fujiyama. Gut 2003
26

Paradoxical gastrointestinal effects of interleukin-17 blockers.
Marine Fauny, David Moulin, Ferdinando D'Amico, Patrick Netter, Nadine Petitpain, Djesia Arnone, Jean-Yves Jouzeau, Damien Loeuille, Laurent Peyrin-Biroulet. Ann Rheum Dis 2020
66
26

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Christopher E M Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, Carle Paul, Alan Menter, Gregory S Cameron, Janelle Erickson, Lu Zhang, Roberta J Secrest,[...]. Lancet 2015
553
21

Inflammatory bowel disease events after exposure to interleukin 17 inhibitors secukinumab and ixekizumab: Postmarketing analysis from the RADAR ("Research on Adverse Drug events And Reports") program.
Kelsey A Orrell, Morgan Murphrey, Ryan C Kelm, Harrison H Lee, David R Pease, Anne E Laumann, Dennis P West, Beatrice Nardone. J Am Acad Dermatol 2018
24
21


A protective function for interleukin 17A in T cell-mediated intestinal inflammation.
William O'Connor, Masahito Kamanaka, Carmen J Booth, Terrence Town, Susumu Nakae, Yoichiro Iwakura, Jay K Kolls, Richard A Flavell. Nat Immunol 2009
589
21

A case of new onset ulcerative colitis following secukinumab treatment.
David N Johnston, Rajesh Veettil. Br J Hosp Med (Lond) 2019
5
100

Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis-A Nationwide 20-Year Cohort Study.
Alexander Egeberg, Jacob P Thyssen, Johan Burisch, Jean-Frederic Colombel. J Invest Dermatol 2019
25
21

New Onset of Inflammatory Bowel Disease in Three Patients Undergoing IL-17A Inhibitor Secukinumab: A Case Series.
Marta Vernero, Marco Astegiano, Davide Giuseppe Ribaldone. Am J Gastroenterol 2019
16
31

Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation.
Joseph R Maxwell, Yu Zhang, William A Brown, Carole L Smith, Fergus R Byrne, Mike Fiorino, Erin Stevens, Jeannette Bigler, John A Davis, James B Rottman,[...]. Immunity 2015
208
21

Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis.
Shusuke Uchida, Naoki Oiso, Yoriaki Komeda, Masatoshi Kudo, Akira Kawada. Eur J Dermatol 2019
8
62

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, Jolanta Weglowska, Lluis Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco Kerdel,[...]. N Engl J Med 2015
495
21

Correlations between psoriasis and inflammatory bowel diseases.
Nevena Skroza, Ilaria Proietti, Riccardo Pampena, Giorgio La Viola, Nicoletta Bernardini, Francesca Nicolucci, Ersilia Tolino, Sara Zuber, Valentina Soccodato, Concetta Potenza. Biomed Res Int 2013
61
21

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.
Luke Jostins, Stephan Ripke, Rinse K Weersma, Richard H Duerr, Dermot P McGovern, Ken Y Hui, James C Lee, L Philip Schumm, Yashoda Sharma, Carl A Anderson,[...]. Nature 2012
21

Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors.
Keira A Fieldhouse, Samantha Ukaibe, Erika L Crowley, Reena Khanna, Ashley O'Toole, Melinda J Gooderham. Drugs Context 2020
24
21

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd-Ruediger Burmester, David H Adams, Lisa Kerr, Chin Lee, Catherine L Shuler,[...]. Lancet 2017
219
17


Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
Bruce Strober, Craig Leonardi, Kim A Papp, Ulrich Mrowietz, Mamitaro Ohtsuki, Robert Bissonnette, Laura K Ferris, Carle Paul, Mark Lebwohl, Daniel K Braun,[...]. J Am Acad Dermatol 2017
76
17


Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
Peter C M van de Kerkhof, Christopher E M Griffiths, Kristian Reich, Craig L Leonardi, Andrew Blauvelt, Tsen-Fang Tsai, Yankun Gong, Jiaqing Huang, Charis Papavassilis, Todd Fox. J Am Acad Dermatol 2016
193
17

A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis.
Dean Ehrlich, Nimah Jamaluddin, Joseph Pisegna, David Padua. Case Rep Gastrointest Med 2018
19
21

[Aphthous mouth ulcers as an initial manifestation of sécukinumab-induced inflammatory bowel disease].
X Grimaux, S Leducq, P Goupille, A Aubourg, E Miquelestorena-Standley, M Samimi. Ann Dermatol Venereol 2018
9
44

Emergence of Inflammatory Bowel Disease During Treatment With Secukinumab.
María José Fobelo Lozano, Reyes Serrano Giménez, Manuel Castro Fernández. J Crohns Colitis 2018
35
17

Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis.
Johan Burisch, Wolfgang Eigner, Stefan Schreiber, Daniel Aletaha, Wolfgang Weninger, Michael Trauner, Walter Reinisch, Neeraj Narula. PLoS One 2020
16
25

IL-17 Signaling: The Yin and the Yang.
Nilesh Amatya, Abhishek V Garg, Sarah L Gaffen. Trends Immunol 2017
295
17

IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting.
Alexander R Moschen, Herbert Tilg, Tim Raine. Nat Rev Gastroenterol Hepatol 2019
172
17

Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.
Craig Leonardi, Robert Matheson, Claus Zachariae, Gregory Cameron, Linda Li, Emily Edson-Heredia, Daniel Braun, Subhashis Banerjee. N Engl J Med 2012
705
13


Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).
Andrew Blauvelt, Melinda Gooderham, Lars Iversen, Susan Ball, Lu Zhang, Noah O Agada, Kristian Reich. J Am Acad Dermatol 2017
77
13

The IL-17 Family of Cytokines in Health and Disease.
Mandy J McGeachy, Daniel J Cua, Sarah L Gaffen. Immunity 2019
418
13

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
A Deodhar, P J Mease, I B McInnes, X Baraliakos, K Reich, A Blauvelt, C Leonardi, B Porter, A Das Gupta, A Widmer,[...]. Arthritis Res Ther 2019
141
13

Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.
C Ryan, A Menter, L Guenther, A Blauvelt, R Bissonnette, K Meeuwis, J Sullivan, J C Cather, G Yosipovitch, A B Gottlieb,[...]. Br J Dermatol 2018
53
13

Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
Carle Paul, Christopher E M Griffiths, Peter C M van de Kerkhof, Lluís Puig, Yves Dutronc, Carsten Henneges, Martin Dossenbach, Kristin Hollister, Kristian Reich. J Am Acad Dermatol 2019
54
13

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.
Atul Deodhar, Denis Poddubnyy, Cesar Pacheco-Tena, Carlo Salvarani, Eric Lespessailles, Proton Rahman, Pentti Järvinen, Juan Sanchez-Burson, Karl Gaffney, Eun Bong Lee,[...]. Arthritis Rheumatol 2019
90
13


Safety of biologics in psoriasis.
Masahiro Kamata, Yayoi Tada. J Dermatol 2018
45
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.